


# RDD 2026

*Respiratory Drug Delivery*



**Westin Kierland**  
**Scottsdale, Arizona**  
**May 10 – 14, 2026**



# RDD2026

Respiratory Drug Delivery

Westin Kierland, Phoenix, Arizona  
May 10–14, 2026

Conference Supporters



SUNDAY • MAY 10 • 2026

3:00 – 7:00 p.m.	<b>Registration</b>	<i>Culturekeepers Registration</i>
7:30 – 9:30 p.m.	<b>Welcome Reception</b> <i>Sponsored by Our Conference Supporters</i>	<i>Marshall's Outpost</i>

MONDAY • MAY 11 • 2026

7:30 a.m.	<b>Continental Breakfast Registration</b>	<i>Vista Morada Culturekeepers Registration</i>
8:30 a.m.	<b>Welcome and Introduction</b> Richard N. Dalby, Ph.D. Professor, School of Pharmacy University of Maryland, Baltimore, Maryland	<i>Trailblazers Ballroom</i>
8:45 a.m.	<b>Presentation of Charles G. Thiel Award</b> Michael Hindle, Ph.D. Professor, School of Pharmacy Virginia Commonwealth University, Richmond, Virginia	<i>Trailblazers Ballroom</i>
9:00 a.m.	<b>Keynote</b> <i>Sponsored by Our Conference Supporters</i>  Moderator: Joanne Peart, Ph.D.  <b><i>Implications of the IBCS on Molecule Design and Particle Engineering of Medicines for Inhalation</i></b> Jeffrey G. Weers Ph.D., FAAPS, FISAM, Independent Consultant, Bainbridge Island, Washington	<i>Trailblazers Ballroom</i>
10:00 a.m.	<b>POSTERS &amp; EXHIBITION</b> <b>Light Refreshments Served</b> Posters & Exhibit Tables will be available for viewing between 10:00 a.m. and 7:00 p.m.	<i>Kierland Ballroom</i>
10:30 a.m. - 12:00 p.m.	<b>SESSION 1: Disrupt, Repurpose, Deliver: The Future Inhaled and Nasal Pipeline</b>  Moderator: Jayne E. Hastedt, Ph.D.	<i>Trailblazers Ballroom</i>
10:30 a.m.	<b><i>Therapeutic Landscape Evolution: Technologies Shaping the Future of Pulmonary and Nasal Drug Delivery</i></b> M. Geraldine Venthoye, Ph.D., Independent Advisor, Basel, Switzerland	
11:00 a.m.	<b><i>Progress in Inhaled Drug Delivery for Non-Small Cell Lung Cancer (NSCLC): A Non-invasive Pathway to Targeted Therapy</i></b> Nitesh K. Kunda, Ph.D., St. John's University, Jamaica, New York	
11:30 a.m.	<b><i>Repurposing GLP-1 Receptor Agonists for Pulmonary and Nasal Delivery</i></b> Francesca Buttini, Ph.D., University of Parma, Parma, Italy	
12:00 p.m.	<b>SESSION 1 ENDS • LUNCH</b>	

12:00 p.m. - 2:00 p.m.	<b>Posters and Exhibition</b> <b>“Grab and Go” Lunch</b>	<i>Kierland Ballroom</i>
2:00 p.m. - 3:00 p.m.	<b>SESSION 2: New Molecules Need New Methods</b>	<i>Trailblazers Ballroom</i>
	Moderator: Philip J. Kuehl, Ph.D.	
2:00 p.m.	<b><i>Translational In Vitro Screening Approach to Support the Development of Dry Powder Inhalation Products by Predicting Clinical Bioavailability</i></b>	
	Dina Morais, Ph.D., Hovione, Lisbon, Portugal	
2:30 p.m.	<b><i>Building Analytical Best Practices for Respiratory Biologics: Raiding the Biological and Respiratory Toolboxes</i></b>	
	Mark Parry, Ph.D., Intertek, Melbourn, United Kingdom	
3:00 p.m.	<b>SESSION 2 ENDS • POSTERS &amp; EXHIBITION</b> <b>Light Refreshments Served</b>	<i>Kierland Ballroom</i>
3:30 p.m. - 5:00 p.m.	<b>SESSION 3: Posters on the Podium</b>	<i>Trailblazers Ballroom</i>
	Moderators: Daniela Traini, Ph.D. and Elizabeth R. Bielski, Ph.D.	
	Poster authors chosen by the Editorial Team present their work during a fast-paced podium session.	
3:35 p.m.	<b><i>Replacing Sugar Excipient with Polymyxins to Improve Dosing of a Dry Powder Teixobactin-lipopeptide Hybrid for the Treatment of Pulmonary Infections</i></b>	
	Sara Maloney Norcross, Ph.D., RTI International, Durham, North Carolina	
3:45 p.m.	<b><i>Medium Chain Length Polyhydroxyalkanoate Nanoparticles for Controlled Drug Delivery to the Lung</i></b>	
	Edward Attenborough, Ph.D., Monash University, Melbourne, Australia	
3:55 p.m.	<b><i>Pulmonary Delivery of Ginkgetin Attenuates Lung Fibrosis in a Rat Model</i></b>	
	Cimone Richardson, B.Sc., Virginia Commonwealth University, Richmond, Virginia	
4:05 p.m.	<b><i>Use of a Modified Next Generation Impactor (mNGI) and Franz Cell for Characterization of the In Vitro Dissolution Performances of Innovator and Generic Dry Powder Inhalers</i></b>	
	Dipesh Khanal, Ph.D., University of Sydney, Sydney, Australia	

## MONDAY • MAY 11 • 2026 *continued*

	<b>SESSION 3 (continued)</b>	<i>Trailblazers Ballroom</i>
4:15 p.m.	<b><i>Particle Level Assessment of Size and Composition as a Function of Aerosol Particle Size Using Optical Photothermal Infrared Microscopy: Comparison of Fluticasone/Salmeterol/Lactose in Advair Diskus and Wixela Inhub</i></b> Teri Ross, M.Sc., University of Alabama, Birmingham, Alabama	
4:25 p.m.	<b><i>In Silico Evaluation of Nasal Spray Plume Angle and Ovality: Effect on Regional Nasal Deposition</i></b> Jan de Backer, Ph.D., FLUIDDA, New York, USA	
4:35 p.m.	<b><i>Rapid Stability Modeling as a Predictor for Long-Term Standard Stability Testing of Dry Powder Inhalers</i></b> Anna Catton, M.Sc., University of Bristol, Bristol, United Kingdom	
4:45 p.m.	<b><i>Predicting Pulmonary Drug Deposition Using Real-Time Connected Inhalation Data</i></b> Ulf Krüger, B.Eng., PULMOTREE, Munich, Germany	
4:55 p.m.	<b>Presentation of VCU RDD Peter R. Byron Graduate Student Award</b>	
5:00 p.m.	<b>SESSION 3 ENDS</b>	
5:00 p.m. - 7:00 p.m.	<b>Posters and Exhibition Evening Reception</b> <b><i>Bringing Science, Innovation and People Together</i></b>	<i>Kierland Ballroom</i>

## TUESDAY • MAY 12 • 2026

7:30 a.m.	<b>Continental Breakfast Registration</b>	<i>Vista Morada Culturekeepers Registration</i>
8:30 a.m.	<b>POSTERS &amp; EXHIBITION Light Refreshments Served</b> Posters & Exhibit Tables will be available for viewing between 8:30 a.m. and 7:00 p.m.	<i>Kierland Ballroom</i>
8:30 a.m. - 9:30 a.m.	<b>SESSION 4: Connected Inhalers: From Digital Dilemma to Design Reality</b> Moderator: John N. Pritchard, Ph.D.	<i>Trailblazers Ballroom</i>
8:30 a.m.	<b><i>The Digital Dilemma: The Continued Case for Connected Inhalers</i></b> Mark Milton-Edwards, M.B.A., Digital Medical Innovations, Macclesfield, United Kingdom	
9:00 a.m.	<b><i>Design for the Future: Navigating the Pathway to Successful Complex Electromechanical Devices</i></b> Andreas M. Meliniotis, B.Eng., Phillips Medisize, Cambridge, United Kingdom	
9:30 a.m.	<b>SESSION 4 ENDS • POSTERS &amp; EXHIBITION Light Refreshments Served</b>	<i>Kierland Ballroom</i>

10:00 a.m. - 12:00 p.m.     **SESSION 5: Simulation to Submission:** *Trailblazers Ballroom*  
***In Silico Strategies for Deposition and Bioequivalence***

Moderator: Jan de Backer, Ph.D.

10:00 a.m.     ***Machine Learning (ML) and Artificial Intelligence (AI) in Generic Drug Development of Orally Inhaled Drug Products***  
 Steven Chopski, Ph.D.,  
 U.S. Food and Drug Administration, Silver Spring, Maryland

10:30 a.m.     ***Accelerating and De-Risking Inhaled Drug Development with In Silico Tools***  
 Victoria Legh-Land, Ph.D.,  
 Microsol Science, Bristol, United Kingdom

11:00 a.m.     ***In Silico Modeling to Identify Alternatives to Charcoal Block Pharmacokinetic Bioequivalence Studies***  
 Ross Walenga, Ph.D.,  
 U.S. Food and Drug Administration, Silver Spring, Maryland

11:30 a.m.     ***Data Driven Design in Respiratory and Nasal Product Development***  
 Chairperson: Jan de Backer, Ph.D.,  
 FLUIDDA, New York, USA

**Panel:**

Steven Chopski, U.S. Food and Drug Administration  
 Victoria Legh-Land, Microsol Science  
 Mark Milton-Edwards, Digital Medical Innovations  
 Andreas Meliniotis, Phillips Medisize  
 Ross Walenga, U.S. Food and Drug Administration

---

12:00 p.m.     **SESSION 5 ENDS • LUNCH**

---

12:00 p.m. - 2:00 p.m.     **Posters and Exhibition** *Kierland Ballroom*  
**"Grab and Go" Lunch**

---

2:00 p.m. - 5:00 p.m.     **SESSION 6: WORKSHOPS**

The following companies will host 45-minute interactive presentations on new technologies related to aerosol drug delivery. Meeting participants may select and attend **THREE** of these sessions.

*Refreshments will be available throughout the afternoon.*

2:00 p.m.     **Workshop Selection #1**

3:00 p.m.     **Workshop Selection #2**

4:00 p.m.     **Workshop Selection #3**

---

**TUESDAY • MAY 12 • 2026 *continued***

	From Bench to Biologic: A Hands-On Journey to Creating a Dry Powder Inhaler or Nebulizer Product	<i>Merriam</i>
	Towards the Ultimate High Performance, Low Carbon pMDI: The Role of Valves in the Net Zero Journey	<i>Cushing</i>
	Prepare For Launch: Ensuring your Spray-Dried Inhalation Product is Commercial Ready	<i>Tribal</i>
	Advancing Dissolution Testing for Inhaled Drug Products	<i>Sitgreaves</i>
	Exploring the Drug-Nebulizer Combination Pathway: Next Generation Nebulizers for New Respiratory Medicines	<i>Powell</i>
	Innovative Strategies in Nasal Powder Drug Delivery: Device Design, Advanced Formulations, and Analytical Approaches	<i>Pathfinders</i>
	Winning the Hand You're Dealt: An Interactive Workshop on Developing Innovative Spray-Dried Products	<i>Mapmakers</i>
	Are You Being Left Behind? Why Partnership Is Critical in Achieving a Successful Low-GWP Propellant Transition	<i>Kierland 4A</i>
	Patient-Centric Product Development: Maximizing the Chances of Success in the Clinic and Beyond	<i>Kierland 4B</i>
	Enhancing <i>In Vitro</i> Tools for Reformulating pMDIs with Low-GWP Propellants: Realistic Regional Deposition Models	<i>Whipple</i>
	Building Regulatory Confidence in LGWP Propellant, HFO-1234ze(E), through Science and Collaboration	<i>Kierland 4C</i>
5:00 p.m.	<b>SESSION 6 ENDS</b>	
5:00 - 7:00 p.m.	<b>Posters and Exhibition Evening Reception</b> <i>Bringing Science, Innovation and People Together</i>	<i>Kierland Ballroom</i>

8:00 a.m.	<p><b>Continental Breakfast</b></p> <p><b>Networking and Recreation Break</b> Participants can play golf, tennis, take an excursion, visit the spa, or relax.</p>	Vista Morada
1:30 p.m. - 3:00 p.m.	<p><b>SESSION 7: Designing Intranasal Delivery Systems for Deposition, Retention, and Scale</b></p> <p>Moderator: Julie D. Suman, Ph.D.</p>	Trailblazers Ballroom
1:30 p.m.	<p><b>Advancing Intranasal Drug Delivery: Insights into Regional Deposition across Age and Disease</b> Laleh Golshahi, Ph.D., Virginia Commonwealth University, Richmond, Virginia</p>	
2:00 p.m.	<p><b>A Quantitative Framework for Modulating Mucus Viscoelasticity to Extend Nasal Residence of Antiviral Proteins</b> Ashlee Brunaugh, Pharm.D., Ph.D., University of Michigan, Ann Arbor, Michigan</p>	
2:30 p.m.	<p><b>Designing Nasal Powders for Biologics: Formulation, Process Design and Manufacturability Considerations</b> Kimberly B. Shepard, Ph.D., Lonza, Bend, Oregon</p>	
3:00 p.m.	<p><b>SESSION 7 ENDS • REFRESHMENTS</b></p>	Vista Morada
3:30 p.m. - 5:00 p.m.	<p><b>SESSION 8: Powders that Perform: Next-Generation DPI Therapies</b></p> <p>Moderator: Paul M. Young, Ph.D.</p>	Trailblazers Ballroom
3:30 p.m.	<p><b>Designing Synergistic Antibiotic Inhalation Powder Formulations to Treat Multi-Drug Resistant Lung Infections</b> Qi (Tony) Zhou, Ph.D., Purdue University, West Lafayette, Indiana</p>	
4:00 p.m.	<p><b>From Concept to Commercialization: Scaling the Print® Particle Platform for High Dose Treprostinil Delivery</b> Derek Schorzman, Ph.D., Liquidia Technologies, Morrisville, North Carolina</p>	
4:30 p.m.	<p><b>Exploring Aerosolized Powder Behavior in Brand and Generic DPIs using Advanced Imaging Techniques</b> Susan Boc, Ph.D., U.S. Food and Drug Administration, Silver Spring, Maryland</p>	
5:00 p.m.	<p><b>SESSION 8 ENDS</b></p>	
6:30 p.m.	<p><b>Cocktail Reception</b></p>	Vista Morada
7:30 p.m.	<p><b>Dinner and Dancing</b></p> <p><i>Sponsored by Our Conference Supporters</i></p>	Kierland Ballroom

7:30 a.m. **Continental Breakfast Registration** *Vista Morada  
Culturekeepers Registration*

8:30 a.m. - 12:00 p.m. **SESSION 9: The MDI at 70: Evolving Science and Regulation** *Trailblazers Ballroom*

Moderator: Stephen W. Stein, M.S.

8:30 a.m. ***New Perspectives on Metering Valve Filling and Emptying Using Synchrotron X-Ray Techniques***

Thomas Daly, B.Eng.,  
University of Hertfordshire, Hatfield, and Bepak, King's Lynn, United Kingdom

9:00 a.m. ***Beyond One-Size-Fits-All: Expanding the Design Space for Next Generation Propellant Formulations***

Lucas Silva, B.Sc.,  
Nanopharm, an Aptar Pharma Company, Cwmbran, United Kingdom

9:30 a.m. **REFRESHMENTS** *Vista Morada*

10:00 a.m. ***U.S. FDA Updates on Key In Vitro Bioequivalence Assessments for Metered Dose Inhalers***

Elizabeth Bielski, Ph.D.,  
U.S. Food and Drug Administration, Silver Spring, Maryland

10:30 a.m. ***An Evolving Regulatory Landscape: U.S. FDA's Evidence Based Perspectives on Next Generation Propellant Product Transitions***

Bryan Newman, Ph.D. and Markham Luke, M.D., Ph.D.,  
U.S. Food and Drug Administration, Silver Spring, Maryland

11:00 a.m. ***Explore with Experts: Building a Sustainable Future The Winds of Change: Have We Finally Reached the Nirvana of a More Sustainable pMDI?***

Chairperson: Nick Smalley, B.Sc.,  
Kindeva, Loughborough, United Kingdom

**Panel:**

Elizabeth Bielski, U.S. Food and Drug Administration  
Markham Luke, U.S. Food and Drug Administration  
Bryan Newman, U.S. Food and Drug Administration  
Lucas Silva, Nanopharm, an Aptar Pharma Company  
Ross Walenga, U.S. Food and Drug Administration

12:00 p.m. **SESSION 9 ENDS**

12:00 p.m. - 2:00 p.m. **Luncheon** *Vista Morada*  
***Sponsored by Our Conference Supporters***



2:00 p.m. **END OF RESPIRATORY DRUG DELIVERY 2026**